Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00145600 · ClinicalTrials.gov registry record · Phase 2
Therapy for Pediatric Hodgkin Lymphoma
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 296
- Enrollment target
NCT00145600 is a Phase 2 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 296 participants.
The verdict
NCT00145600, a Phase 2 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 296 participants
- Enrollment target
Study Summary
With the success of current chemotherapy for Hodgkin's disease, the goal of this protocol is to maintain the currently successful cure rate and reduce treatment related side effects and long term toxicity. The main purpose of this study is to estimate the event free survival of patients treated with risk-adapted therapy compared to historical controls.
Interventions
- DRUG 12 Week Stanford V Chemotherapy
- DRUG 4 cycles of VAMP chemotherapy
- DRUG 2 alternating cycles of VAMP/COP chemotherapy
- DRUG 3 alternating cycles of VAMP/COP chemotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 296 participants |
| Start Date | 2000-03-02 |
| Est. Completion | 2021-11-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00145600
The ClinicalTrials.gov registry entry for NCT00145600 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 296 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 12 Week Stanford V Chemotherapy is the first listed.
NCT00145600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00145600 about?
NCT00145600 is a clinical study titled "Therapy for Pediatric Hodgkin Lymphoma". With the success of current chemotherapy for Hodgkin's disease, the goal of this protocol is to maintain the currently successful cure rate and reduce treatment related side effects and long term toxicity. The main purpose of this study is to estimate the event free survival of patients treated with...
What is the current status of trial NCT00145600?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 296 participants. The study started on 2000-03-02. Estimated completion is 2021-11-05.
What interventions are being tested in trial NCT00145600?
The interventions under investigation include: 12 Week Stanford V Chemotherapy (DRUG), 4 cycles of VAMP chemotherapy (DRUG), 2 alternating cycles of VAMP/COP chemotherapy (DRUG), 3 alternating cycles of VAMP/COP chemotherapy (DRUG).
Who is sponsoring clinical trial NCT00145600?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.